Cite
APA Citation
Cusi, K., Alkhouri, N., Harrison, S. A., Fouqueray, P., Moller, D. E., Hallakou-Bozec, S., Bolze, S., Grouin, J., Jeannin Megnien, S., Dubourg, J., & Ratziu, V. (2021). efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. Lancet gastroenterology and hepatology, 6, 889–902. http://access.bl.uk/ark:/81055/vdc_100144510712.0x000005